Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

M1318

Sigma-Aldrich

Milnacipran hydrochloride

≥98% (HPLC), solid

Synonym(s):

(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride, F 2207, Midalcipran, Toledomin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H22N2O · HCl
CAS Number:
101152-94-7
Molecular Weight:
282.81
MDL number:
MFCD00901293
UNSPSC Code:
12352200
PubChem Substance ID:
329817868
NACRES:
NA.77

description

Relative stereochemistry
Store with desiccants

Assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: 19 mg/mL

originator

Cypress Bioscience

storage temp.

2-8°C

SMILES string

Cl[H].CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c2ccccc2

InChI

1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1

InChI key

XNCDYJFPRPDERF-PBCQUBLHSA-N

Biochem/physiol Actions

Serotonin and norepinephrine reuptake inhibitor (SNRI)

Features and Benefits

This compound was developed by Cypress Bioscience. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

M1318-50MG:
M1318-BULK:
M1318-10MG:
M1318-VAR:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
099K4612V
099M4612V
099K4612
047K46204
047K46203

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Okkerse et al.
European journal of pain (London, England), 21(3), 494-506 (2016-09-22)
Serotonin-norepinephrine reuptake inhibitors inhibit the reuptake of serotonin and noradrenalin and are used in the treatment of neuropathic pain. Animal studies suggest that milnacipran co-administered with opioids may potentiate the analgesic effect of μ-opioid receptor agonists. This study hypothesized that
Junji Uno et al.
Pharmacology, 99(1-2), 89-98 (2016-10-25)
To investigate the potential inhibitory effects of 18 clinically available antidepressants on acetylcholine (ACh)-induced contractions in guinea pig urinary bladder smooth muscle (UBSM) in order to predict whether they may induce voiding impairment. Concentration-response curves for ACh-induced contractions in guinea
Hiroshi Kawai et al.
Biological & pharmaceutical bulletin, 41(2), 213-219 (2018-02-02)
Biological rhythms are thought to be related to the pathogenesis and therapy of various diseases including depression. Here we investigated the influence of circadian rhythms on the antidepressant activity of the dual-action serotonin-noradrenaline reuptake inhibitor (SNRI) milnacipran. Rats administered milnacipran
C Moret et al.
Neuropharmacology, 24(12), 1211-1219 (1985-12-01)
The present study of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane(Z) hydrochloride, was undertaken to determine its biochemical profile. The properties of midalcipran, in inhibiting the uptake of monoamines were tested and compared with that of imipramine. In vitro, midalcipran was found to
David T Wong et al.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 58, 169-222 (2002-06-25)
Preclinical and clinical studies support the rationale that development of single molecules, which would promote serotonergic and noradrenergic neurotransmission by inhibiting simultaneously the uptake of both monoamines, would potentially result in improved antidepressant drugs. Currently, the dual inhibitors of serotonin
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service